Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's ...

Shares of GSK PLC GSK inched up 0.98% to £14.39 Monday, on what proved to be an all-around positive trading session for the ...

Bristol Myers leans on new launches to offset legacy drug declines, while GSK's diverse portfolio and strong HIV lineup keep growth on track.

Dynavax Technologies has revealed promising topline outcomes from the initial part of its Phase I/II clinical trial, ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

British drugmaker GSK said on Monday that the U.S. Food and Drug Administration has accepted its application for priority ...

Dynavax (DVAX) stock gains as the company's Z-1018 shingles shot shows immune response comparable to GSK's (GSK) Shingrix vaccine in a Phase 1/2 trial. Read more here.

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

Property developer Hadley Group has sent in its application for a 13-acre redevelopment of the former GSK headquarters in ...

GSK’s share price is still significantly down on the year, despite very robust H1 results, leaving it looking extremely ...